AI assistant
AROA BIOSURGERY LIMITED — Director's Dealing 2023
Mar 30, 2023
64426_rns_2023-03-30_f56b4179-7cca-4b08-94d0-af64fa518ef7.pdf
Director's Dealing
Open in viewerOpens in your device viewer
Appendix 3Y Change of Director’s Interest Notice
Rule 3.19A.2
Appendix 3Y
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.
Introduced 30/09/01 Amended 01/01/11
Name of entity Aroa Biosurgery Limited ARBN 638 867 473
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
| Name of Director | Steven Engle |
|---|---|
| Date of last notice | 27 July 2020 |
Part 1 - Change of director’s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.
| disclosed in this part. | |
|---|---|
| Direct or indirect interest | Direct |
| Nature of indirect interest(including registered holder)Note: Provide details of the circumstances giving rise to therelevant interest. | N/A |
| Date of change | 31 March 2023 |
| No. of securities held prior to change | 226,533 Fully Paid Ordinary Shares633,225 Options exercisable at $0.0979expiring 1 October 2028245,775Options exercisable at $0.75expiring 23 July 2025 |
| Class | Options exercisable at $1.083 expiring 29February 2028 |
| Number acquired | 172,620 |
| Number disposed | - |
| Value/ConsiderationNote: If consideration is non-cash, provide details and estimatedvaluation | Nil |
- See chapter 19 for defined terms.
01/01/2011
Appendix 3Y Page 1
Appendix 3Y Change of Director’s Interest Notice
| No. of securities held after change | 226,533 Fully Paid Ordinary Shares633,225 Options exercisable at $0.0979expiring 1 October 2028245,775Options exercisable at $0.75expiring 23 July 2025172,620 Options exercisable at $1.083expiring 29 February 2028 |
|---|---|
| Nature of changeExample: on-market trade, off-market trade, exercise of options,issue of securities under dividend reinvestment plan, participationin buy-back | Issued on 31 March 2023 pursuant toshareholder approval received at the AnnualGeneral Meeting held on 10 August 2022 |
Part 2 – Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.
| Detail of contract | - |
|---|---|
| Nature of interest | - |
| Name of registered holder | - |
| (if issued securities) | |
| Date of change | - |
| No. and class of securities to which interest | - |
| related prior to change | |
| Note: Details are only required for a contract in relation to which the | |
| interest has changed | |
| Interest acquired | - |
| Interest disposed | - |
| Value/Consideration | - |
| Note: If consideration is non-cash, provide details and an estimated | |
| valuation | |
| Interest after change | - |
Part 3 –[+] Closed period
| Part 3 –+Closed period | Part 3 –+Closed period | |
|---|---|---|
| Were the interests in the securities or | No | |
| contracts detailed above traded | during a | |
| +closedperiodwhereprior | written | |
| clearance was required? | ||
| If so, was prior written clearance | provided | N/A |
| to allow the trade to proceed during this | ||
| period? | ||
| If prior written clearance was provided, on | N/A | |
| what date was this provided? |
- See chapter 19 for defined terms.
Appendix 3Y Page 2
01/01/2011